Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial

[1]  S. Jóźwiak,et al.  Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures , 2018, Epilepsy & Behavior.

[2]  C. Elger,et al.  Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study , 2018, Epilepsia.

[3]  C. Elger,et al.  Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies , 2017, CNS neuroscience & therapeutics.

[4]  P. Soares-da-Silva,et al.  Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action , 2015, Pharmacology research & perspectives.

[5]  M. Sperling,et al.  Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial , 2014, Epilepsia.

[6]  J. Cramer,et al.  Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate , 2017, Epilepsy & Behavior.

[7]  C. Kerr,et al.  The impact of epilepsy on children and adult patients’ lives: Development of a conceptual model from qualitative literature , 2011, Seizure.

[8]  E. Ben-Menachem,et al.  Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy , 2010, Epilepsy Research.

[9]  A. Gil-Nagel,et al.  Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures , 2009, Acta neurologica Scandinavica.

[10]  C. Elger,et al.  Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study , 2009, Epilepsia.

[11]  Sylvain Rheims,et al.  Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy , 2008, PLoS medicine.

[12]  A. Falcão,et al.  Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy , 2008, Journal of clinical pharmacology.

[13]  O. Dulac,et al.  Antiepileptic Drug Development in Children , 2008, Drugs.

[14]  P. Edrich,et al.  Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures. , 2006, Epileptic disorders : international epilepsy journal with videotape.

[15]  R. Hays,et al.  Seizure Reduction and Quality of Life Improvements in People with Epilepsy , 2002, Epilepsia.

[16]  L. Lamoreaux,et al.  Gabapentin as Add‐On Therapy in Children with Refractory Partial Seizures: A 12‐Week, Multicentre, Double‐Blind, Placebo‐Controlled Study , 1999, Epilepsia.

[17]  R. Cunha,et al.  Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. , 1999, Journal of medicinal chemistry.

[18]  O. Dulac,et al.  Antiepileptic drug development in children: considerations for a revisited strategy. , 2008, Drugs.